arrow
L

Leslie K. Ballas

University of California Los Angeles Medical Center
H指数:19
被引数:1,715

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Are Urologists and/or Radiation Oncologists Biased when Reporting of Advantages and Disadvantages of Surgery versus Radiation in Consultations for Early-Stage Prostate Cancer?

泌尿科医生和/或放射肿瘤科医生在咨询早期前列腺癌手术与放疗的优缺点时是否存在偏见?

2026-01-010
PRE
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial

立体定向调强放疗在根治性前列腺切除术后的应用(SCIMITAR):一项II期临床试验的4年结果

2025-09-300
PRE
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy A Nonrandomized Clinical Trial

根治性前列腺切除术后立体定向调强放疗的患者报告结果非随机临床试验

2025-05-151
PRE
Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups

淋巴瘤试验的辐射目标命名: 国家临床试验网络小组的共识建议

2024-12-010
PRE
Impact of Myc-Altered Pathology on Radiation Therapy Efficacy Among Patients With Relapsed/Refractory Large-B Cell Lymphoma A Collaborative Study by ILROG

Myc-改变的病理对复发/难治性大B细胞淋巴瘤患者放疗疗效的影响 ILROG合作研究

2024-11-010
PRE
Intra-fractional geometric and dose/volume metric variations of magnetic resonance imaging-guided stereotactic radiotherapy of prostate bed after radical prostatectomy

前列腺癌根治术后磁共振成像引导下前列腺床立体定向放射治疗的几何和剂量/体积分数变化

2024-04-011
OAAI
The role of adaptive planning in margin-reduced, MRI-guided stereotactic body radiotherapy to the prostate bed following radical prostatectomy: Post-hoc analysis of a phase II clinical trial

适应性计划在根治性前列腺切除术后前列腺床的边缘减少,MRI引导的立体定向放射治疗中的作用: II期临床试验的事后分析

2023-06-0111
PRE
Consensus Quality Measures and Dose Constraints for Prostate Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel
2023-03-015
PRE
Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial
2023-01-0128
PRE